Targeting Cognitive Immunization in Depression
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03460574 |
Recruitment Status :
Completed
First Posted : March 9, 2018
Last Update Posted : August 23, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Major Depressive Disorder | Behavioral: INFORMATION Behavioral: SALIENCE Behavioral: ATTENTION Behavioral: CONTROL | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 135 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Parallel Assignment Participants are assigned to one of four experimental groups in parallel for the duration of the study |
Masking: | Single (Investigator) |
Masking Description: | The investigator randomly assigns participants to one of the experimental conditions. Participants are not aware which experimental condition they are allocated to. |
Primary Purpose: | Treatment |
Official Title: | How Can Change of Dysfunctional Expectations in Major Depression be Enhanced? An Experimental Study Targeting Cognitive Immunization |
Actual Study Start Date : | October 14, 2017 |
Actual Primary Completion Date : | April 30, 2018 |
Actual Study Completion Date : | August 21, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: INFORMATION
Participants in this condition receive a manipulation suggesting that the performance test "TEMINT", they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted.
|
Behavioral: INFORMATION
After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction. |
Experimental: SALIENCE
Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
|
Behavioral: SALIENCE
After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants. |
Experimental: ATTENTION
Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
|
Behavioral: ATTENTION
Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback. |
Experimental: CONTROL
Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
|
Behavioral: CONTROL
This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm. |
- Performance Expectations Scale - generalized [ Time Frame: Directly prior to the performance test and directly after completing the performance test ]Change from Baseline to Postassessment in generalized performance expectations
- Performance Expectations Scale - task-specific [ Time Frame: Directly prior to the performance test and directly after completing the performance test ]Change from Baseline to Postassessment in task-specific performance expectations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- current diagnosis of Major Depressive Disorder
- at least 18 years old
- sufficient German language knowledge
Exclusion Criteria:
- none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03460574
Germany | |
Schoen Klinik Bad Arolsen | |
Bad Arolsen, Hessen, Germany, 34454 |
Principal Investigator: | Tobias Kube, M. Sc. | Philipps University Marburg Medical Center |
Responsible Party: | Philipps University Marburg Medical Center |
ClinicalTrials.gov Identifier: | NCT03460574 |
Other Study ID Numbers: |
2017-39k |
First Posted: | March 9, 2018 Key Record Dates |
Last Update Posted: | August 23, 2018 |
Last Verified: | August 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | No IPD will be shared |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Depressive Disorder Depressive Disorder, Major Mood Disorders Mental Disorders |